Companies
FDA extends Exelixis zanzalintinib review by three months to March 3, 2027
Updated safety and efficacy data prompted more review time for the zanzalintinib–atezolizumab application in metastatic colorectal cancer. The extension does not decide whether the regimen will be approved.